| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/15/2009 | EP2047853A1 The application of marine steroid in preparing the medicine of treating neurons damaging |
| 04/15/2009 | EP2047852A1 Use of flumazenil in the production of a medicament for the treatment of depressive disorders |
| 04/15/2009 | EP2047851A1 Drug formulation containing fibrate medicament and process for producing the same |
| 04/15/2009 | EP2047850A2 Methods for treating diseases through inhibition of the function of molecular chaperones such as protein disulfide isomerases , pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents |
| 04/15/2009 | EP2047849A1 Use of indolocarbazole imides as protein kinase inhibitors for the treatment of hematologic and solid tumors |
| 04/15/2009 | EP2047848A1 Method of treating genetic disease caused by nonsense mutation |
| 04/15/2009 | EP2047847A1 Solid pharmaceutical composition comprising tamsulosin |
| 04/15/2009 | EP2047846A2 Process for stabilizing hydroquinone |
| 04/15/2009 | EP2047845A1 Adhesive preparation |
| 04/15/2009 | EP2047844A2 A method of microencapsulation |
| 04/15/2009 | EP2047760A1 Oral composition enabling increased absorption of cryptoxanthin |
| 04/15/2009 | EP2046960A1 Process for producing arachidonic acid and/or eicosapentaenoic acid in plants |
| 04/15/2009 | EP2046957A1 Fatty acid desaturases and uses thereof |
| 04/15/2009 | EP2046930A2 Rhamnolipid-based formulations |
| 04/15/2009 | EP2046807A2 Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration |
| 04/15/2009 | EP2046804A1 Synthesis of diethyl{ i5" (3 -fluorophenyl) -pyridine-2-yl] methyl} phosphonate used in the synthesis of himbacine analogs |
| 04/15/2009 | EP2046803A1 Imidazothiazole derivatives as mark inhibitors |
| 04/15/2009 | EP2046802A2 Novel 2-substituted methyl penam derivatives |
| 04/15/2009 | EP2046800A1 6-carboxy-normorphinan derivatives, synthesis and uses thereof |
| 04/15/2009 | EP2046799A1 Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them |
| 04/15/2009 | EP2046798A1 Furo [3,2-b]pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors |
| 04/15/2009 | EP2046797A1 Furo [3,2-b]pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors |
| 04/15/2009 | EP2046796A1 Tetrahydrofuro [3, 2 -b]pyrr0l-3-ones as cathepsin k inhibitors |
| 04/15/2009 | EP2046795A1 Furo[3,2-b]pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors |
| 04/15/2009 | EP2046793A2 Fused pyrimido compounds |
| 04/15/2009 | EP2046791A2 Urea derivatives of tropane, their preparation and their therapeutic application |
| 04/15/2009 | EP2046789A2 Labelled analogues of halobenzamides as radiopharmaceuticals |
| 04/15/2009 | EP2046787A1 Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors |
| 04/15/2009 | EP2046786A2 Polymorphic forms of ziprasidone sulfates |
| 04/15/2009 | EP2046783A2 Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3) |
| 04/15/2009 | EP2046782A2 Imidazolylpyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3) |
| 04/15/2009 | EP2046779A2 Modulators of chemokine receptor activity, crystalline forms and process |
| 04/15/2009 | EP2046778A1 Multifunctional bioactive compounds |
| 04/15/2009 | EP2046777A2 Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide |
| 04/15/2009 | EP2046776A2 Methods and apparatus for identifying subject matter in view data |
| 04/15/2009 | EP2046775A1 N-(aminoheteroaryl)-1h-indole-2-carboxamide derivatives, preparation thereof and therapeutic use thereof |
| 04/15/2009 | EP2046774A1 Pyrazole derivatives as cytochrome p450 inhibitors |
| 04/15/2009 | EP2046773A1 Metformin r-(+) lipoate as an antidiabetic agent for control of diabetic hyperglycemia and diabetic complications |
| 04/15/2009 | EP2046769A2 Aldh-2 inhibitors in the treatment of addiction |
| 04/15/2009 | EP2046767A2 Process for preparing diaminophenothiazinium compounds |
| 04/15/2009 | EP2046766A1 Agonists of the sphingosine- 1- phosphate receptor (slp) |
| 04/15/2009 | EP2046764A1 Substituted isoxalines, pharmaceutical compositions containing same, methods of preparing same, and uses of same |
| 04/15/2009 | EP2046763A2 Aurora kinase inhibitors from an encoded small molecule library |
| 04/15/2009 | EP2046762A2 Triazolyl phenyl benzenesulfonamides |
| 04/15/2009 | EP2046761A2 Macrocyclic compounds useful as bace inhibitors |
| 04/15/2009 | EP2046760A1 Macrocyclic lactams |
| 04/15/2009 | EP2046759A1 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors |
| 04/15/2009 | EP2046758A1 Substituted sulphoximines as tie2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| 04/15/2009 | EP2046756A2 Preparation of telmisartan salts |
| 04/15/2009 | EP2046753A2 Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors |
| 04/15/2009 | EP2046749A1 Pharmaceutically acceptable salt and polymorphic forms of flupirtine maleate |
| 04/15/2009 | EP2046748A1 Phenylpentadienoyl derivatives and their use as par 1 antagonists |
| 04/15/2009 | EP2046747A1 Substituted aminomethyl benzamide compounds |
| 04/15/2009 | EP2046746A2 Chemical compounds |
| 04/15/2009 | EP2046739A1 Substituted aniline derivatives |
| 04/15/2009 | EP2046738A1 Enantiomerically pure flavone derivatives for the treatment of poliferative disorders and processes for their preparation |
| 04/15/2009 | EP2046737A2 2-methylene-1 alpha,25-dihydroxy-19,21-dinorvitamin d3 analogs and uses thereof |
| 04/15/2009 | EP2046736A1 Arylsulfanyl compounds and compositions for delivering active agents |
| 04/15/2009 | EP2046734A1 Derivatives of 4-trimethylammonium-3-aminobutyrate and 4-trimethylphosphonium-3-aminobutyrate as cpt-inhibitors |
| 04/15/2009 | EP2046732A1 Improvement of the bioavailability of active substances having an amidine function in medicaments |
| 04/15/2009 | EP2046731A1 Non-nucleoside reverse transcriptase inhibitors |
| 04/15/2009 | EP2046727A1 Positively charged water-soluble prodrugs of diclofenac with very fast skin penetration rate |
| 04/15/2009 | EP2046723A2 Phenylacetic acid derivatives as cox-2 inhibitors |
| 04/15/2009 | EP2046722A2 Beta-3 receptor ligands and their use in therapy |
| 04/15/2009 | EP2046716A1 Substituted 1,3-diphenylpropane derivatives, preparations and uses thereof |
| 04/15/2009 | EP2046715A1 Substituted 1,3-diphenylpropane derivatives, preparations and uses thereof |
| 04/15/2009 | EP2046714A2 Therapeutic compounds |
| 04/15/2009 | EP2046456A2 Carotenoid compositions useful for whitening skin |
| 04/15/2009 | EP2046451A1 Monoamine oxidase inhibitors useful for treating disorders of the outer retina |
| 04/15/2009 | EP2046389A2 Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease |
| 04/15/2009 | EP2046388A2 Formulations for parenteral delivery of compounds and uses thereof |
| 04/15/2009 | EP2046386A2 Peptide compounds for the treatment of hyperexcitability disorders and diseases associated with ion channel dysfunction |
| 04/15/2009 | EP2046366A2 Method of treatment of age-related macular degeneration |
| 04/15/2009 | EP2046361A2 Osteogenic enhancer composition |
| 04/15/2009 | EP2046360A2 Herbal compositions for the treatment of diseases of the oral cavity |
| 04/15/2009 | EP2046358A1 Induction of analgesia in neuropathic pain |
| 04/15/2009 | EP2046355A2 Reduced isoalpha acid based protein kinase modulation cancer treatment |
| 04/15/2009 | EP2046353A2 Tetrahydro-isoalpha acid based protein kinase modulation cancer treatment |
| 04/15/2009 | EP2046348A2 Use of poloxamer for the prevention and/or treatment of heart failure |
| 04/15/2009 | EP2046347A2 Phosphorylated glucomannan polysaccharide for receptor mediated activation and maturation of monocyte-derived dendritic cells |
| 04/15/2009 | EP2046346A1 Novel sglt inhibitors |
| 04/15/2009 | EP2046345A2 Use of escin |
| 04/15/2009 | EP2046344A2 Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes |
| 04/15/2009 | EP2046343A2 Formulations of radioprotective alpha, beta unsaturated aryl sulfones |
| 04/15/2009 | EP2046342A2 Crystalline form a of ibandronic acid and process for the preparation |
| 04/15/2009 | EP2046341A1 Compositions and methods for treating diabetes and neuropsychological dysfunction |
| 04/15/2009 | EP2046340A2 Jak inhibitors for treatment of myeloproliferative disorders |
| 04/15/2009 | EP2046339A1 Rho/rock/p13/akt kinase inhibitors for the treatment of diseases associated with protozoan parasites |
| 04/15/2009 | EP2046338A2 Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions |
| 04/15/2009 | EP2046337A2 Solid forms containing meloxicam with improved buccal taste and process for their preparation |
| 04/15/2009 | EP2046336A2 3-ARYL-6-ARYL-7H-[1,2,4]TRIAZOLO[3,4-b][1,3,4]THIADIAZINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF |
| 04/15/2009 | EP2046335A2 Methods and pharmaceutical preparations for contributing to the treatment of chemotherapy-induced neuropathy |
| 04/15/2009 | EP2046333A2 Thiozolidinedione derivatives as p13 kinase inhibitors |
| 04/15/2009 | EP2046332A2 Concentrated methotrexate solutions |
| 04/15/2009 | EP2046331A1 Use of 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment of mantle cell lymphomas |
| 04/15/2009 | EP2046330A2 Pharmaceutical combinations |
| 04/15/2009 | EP2046329A2 Soluble epoxide hydrolase inhibitors |
| 04/15/2009 | EP2046328A2 Pyridinone diketo acids: inhibitors of hiv replication in combination therapy |
| 04/15/2009 | EP2046327A1 Medical use of cyclin dependent kinases inhibitors |
| 04/15/2009 | EP2046326A2 Annellated pyrrole compounds for cancer management |